OncoSec Medical, Inc. (ONCS) Starts Presentation at 2nd Annual Marcum MicroCap Conference
OncoSec Medical is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for the treatment of solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). ONCS’ clinical programs include three phase 2 clinical trials for ImmunoPulse targeting lethal skin cancers. For more information visit the company’s Web site at www.oncosec.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
